Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer (IBIS II)
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Anastrozole may be effective in preventing breast cancer.
PURPOSE: This randomized clinical trial is studying how well anastrozole works in preventing breast cancer in postmenopausal women who are at increased risk for the disease.
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Prevention
|Official Title:||International Breast Cancer Intervention Study|
- Development of histologically confirmed breast cancer, both invasive and non-invasive with median follow-up at 5 years [ Time Frame: Dec 2013 ]
- Breast cancer mortality with median follow-up at 10 years [ Time Frame: Dec 2018 ]
|Study Start Date:||September 2003|
|Estimated Study Completion Date:||January 2022|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Other Name: Arimidex
Placebo Comparator: placebo
anastrozole 1mg PLACEBO
- Determine the effectiveness of anastrozole in preventing breast cancer in postmenopausal women at increased risk for the disease.
- Determine the role of this drug in preventing estrogen receptor-positive breast cancer in these participants.
- Determine the effect of this drug on breast cancer mortality in these participants.
- Determine the effect of this drug on other cancers, cardiovascular disease, fracture rates, and non-breast cancer deaths in these participants.
- Determine the tolerability and acceptability of side effects of this drug in these participants.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Participants are stratified according to participating center. Participants are randomized to 1 of 2 treatment arms.
- Arm I: Participants receive oral anastrozole daily for 5 years.
- Arm II: Participants receive an oral placebo daily for 5 years. In both arms, treatment continues in the absence of the development of breast cancer (including ductal carcinoma in situ), a drop in the T-score below minus 4, or the occurrence of a new fragility fracture.
Participants are followed for 5 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
ACCRUAL: A total of 3,864 participants were recruited for this study over 10 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00078832
Show 75 Study Locations
|Study Chair:||Jack Cuzick, PhD||Queen Mary's University|